| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/100-1/300 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/40000 | Human,Mouse,Rat |
| Aliases | TAF6L; PAF65A; TAF6-like RNA polymerase II p300/CBP-associated factor-associated factor 65 kDa subunit 6L; PCAF-associated factor 65-alpha; PAF65-alpha |
| Entrez GeneID | 10629; |
| WB Predicted band size | 68kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse |
| Immunogen | Synthesized peptide derived from the N-terminal region of human PAF65α. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.5%BSA and 50% glycerol. |
+ +
以下是关于PAF65α抗体的3篇示例文献(内容为虚构，仅作格式参考)：
---
1. **文献名称**: *PAF65α-mediated transcriptional regulation in embryonic stem cell pluripotency*
**作者**: Yamaguchi S, et al. (2015)
**摘要**: 本研究利用PAF65α特异性抗体，通过ChIP-seq和RNA干扰技术，揭示了PAF65α作为PAF复合体核心组分在维持胚胎干细胞多能性中的关键作用。结果表明，PAF65α通过结合Oct4和Nanog启动子区域，调控其转录活性，缺失会导致多能性丧失。
2. **文献名称**: *PAF65α interacts with HDAC1 to modulate DNA damage response*
**作者**: Wang L, et al. (2018)
**摘要**: 通过免疫共沉淀(使用PAF65α抗体)和质谱分析，研究发现PAF65α与组蛋白去乙酰化酶HDAC1在DNA损伤修复中形成复合物。实验表明，PAF65α-HDAC1互作通过调控染色质重塑影响修复效率，其缺失导致细胞对电离辐射敏感性显著增加。
3. **文献名称**: *PAF65α overexpression as a prognostic marker in acute myeloid leukemia*
**作者**: Li H, et al. (2020)
**摘要**: 采用PAF65α抗体进行免疫组化和Western blot分析，发现急性髓系白血病(AML)患者中PAF65α蛋白表达水平显著升高，且与不良预后相关。机制研究表明，PAF65α通过激活Wnt/β-catenin通路促进白血病细胞增殖。
---
注：以上文献为示例，实际研究中请通过PubMed或Google Scholar检索真实文献。若需具体文章，建议补充蛋白全称或相关功能关键词以缩小范围。
The PAF65α antibody is a research tool designed to detect PAF65α (Polymerase Associated Factor 65 alpha), a subunit of the human PAF1 complex. This evolutionarily conserved multiprotein complex, comprising PAF1. LEO1. CTR9. RTF1. and CDC73. associates with RNA polymerase II (Pol II) to regulate transcription elongation, histone modification, and RNA processing. PAF65α (also termed PAF1C or PD2) plays a critical role in epigenetic regulation by facilitating histone H2B ubiquitination and H3K4 methylation, processes linked to transcriptional activation and chromatin remodeling. It is implicated in stem cell maintenance, oncogenesis, and developmental pathways.
The PAF65α antibody is widely used in molecular biology to study its expression patterns, protein-protein interactions (e.g., with Pol II or histone-modifying enzymes), and subcellular localization via techniques like Western blotting, immunoprecipitation, and immunofluorescence. Dysregulation of PAF65α has been observed in cancers, particularly leukemias and solid tumors, where its overexpression correlates with poor prognosis, making it a potential therapeutic target. Research utilizing this antibody has advanced understanding of transcriptional dysregulation in disease states and the PAF1 complex's role in coupling transcription to chromatin dynamics. Commercial antibodies are typically raised against specific epitopes of human PAF65α and validated for specificity across experimental models.
×
